Capture Gelatrix Manufacturing Rights via Convertible Note Bridge
- Organization
- NSF SBIR Phase I funding structure (research capital without commercial infrastructure)
- Sector
- Orthopedic device strategic acquirers (Stryker, Zimmer, DePuy)
- Location
- Location unspecified
Source reference
Executive summary
Current state
NSF awarded $305K SBIR Phase I funding to CYTROGEN for Gelatrix, a light-curable bone adhesive, creating a research-funded entity with technical validation capital but zero commercial infrastructure, manufacturing partnerships, or market access pathways.
Market catalyst
CYTROGEN has $305K SBIR funding for technical feasibility but zero commercial infrastructure, manufacturing partnerships, or market access. The SBIR program requires a commercialization plan for Phase II but provides no resources to build it, creating a valley of death between research validation and commercial execution.
This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.
Field notes
Intelligence ledger
Add new evidence, corrections, or practical context to this directive. Keep claims attributable to a source where possible.
Sign in to add intelligence or vote on a field note.
Field intel logs: [ 0 ] entries. No operative updates submitted for this directive. Submit intel to claim clearance.